New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case
Open Access
- 16 September 2024
- journal article
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (4) , 361-368
Abstract
Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period.Keywords
This publication has 29 references indexed in Scilit:
- Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAmerican Journal of Clinical Dermatology, 2024
- Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisPediatric Drugs, 2024
- Filaggrin and beyondAnnals of Allergy, Asthma & Immunology, 2023
- Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic DermatitisPediatric Drugs, 2022
- The atopic march and atopic multimorbidity: Many trajectories, many pathwaysJournal of Allergy and Clinical Immunology, 2019
- Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohortsJournal of Allergy and Clinical Immunology, 2018
- Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development StudyJournal of Allergy and Clinical Immunology, 2018
- The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJournal of Allergy and Clinical Immunology, 2014
- Epidemiologic risks for food allergyJournal of Allergy and Clinical Immunology, 2008
- Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 responseEuropean Journal of Immunology, 2004